STOCK TITAN

CalciMedica, Inc. - CALC STOCK NEWS

Welcome to our dedicated page for CalciMedica news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CalciMedica stock.

CalciMedica, Inc. (Nasdaq: CALC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drugs for treating autoimmune disorders, organ transplant rejection, and other immune diseases. The company's primary focus is on developing therapies for life-threatening inflammatory diseases with a high unmet need. Utilizing its proprietary technology, CalciMedica targets the inhibition of calcium release-activated calcium (CRAC) channels. This approach is designed to modulate the immune response and protect against tissue cell injury, offering therapeutic benefits for diseases with no approved therapies.

CalciMedica's lead product candidate, Auxora™, is an intravenous-formulated CRAC channel inhibitor that has shown promising results in multiple clinical trials. The company is currently conducting several significant studies:

  • CARPO Trial: A Phase 2b international, randomized, double-blind, placebo-controlled, dose-ranging trial aimed at establishing Auxora's efficacy in treating acute pancreatitis with accompanying systemic inflammatory response syndrome (SIRS). The trial has successfully enrolled 216 patients, with topline data expected in the second quarter of 2024.
  • CRSPA Study: An investigator-sponsored Phase 1/2 trial focusing on pediatric patients with acute lymphoblastic leukemia (ALL) experiencing asparaginase-induced pancreatic toxicity (AIPT). This study aims to define an optimal pediatric dose for Auxora and is expected to provide additional data by the second half of 2024.
  • KOURAGE Trial: A Phase 2 trial targeting patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This randomized, double-blind, placebo-controlled study plans to evaluate 150 patients, with data anticipated in 2025.

CalciMedica has also secured substantial funding through a securities purchase agreement, raising up to $55 million in gross proceeds. This financing will support ongoing and planned clinical trials, bringing the company closer to achieving its goal of providing effective treatments for critically ill patients.

Recent achievements include the presentation of positive Phase 1/2 CRSPA study results at the 65th Annual American Society of Hematology Meeting and the clearance of an Investigational New Drug (IND) application by the FDA for the KOURAGE trial. Additionally, the company has engaged in a private placement financing, ensuring continued financial health and the ability to pursue pivotal clinical trials.

Founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica is headquartered in La Jolla, CA. For more information, visit www.calcimedica.com.

Rhea-AI Summary

CalciMedica has announced the first patient enrollment in its Phase 2 KOURAGE trial, testing Auxora™ for severe acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF). This trial, supported by clinical and pre-clinical evidence, aims to enroll 150 patients. Participants will receive daily doses of Auxora or placebo and will be evaluated up to 30 days post-dosing. The study includes secondary endpoints like all-cause mortality and kidney function decline over 90 days. Previous trials and preclinical models have shown promising results for Auxora. Topline data are expected in 2025.

With AKI causing 3.7 million hospitalizations annually in the U.S., this trial could pave the way for a novel treatment in a field currently to supportive care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
-
Rhea-AI Summary

CalciMedica, a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies, announced that CEO Rachel Leheny, Ph.D., will present at two upcoming healthcare investment conferences on July 15, 2024. The events include the H.C. Wainwright 3rd Annual Kidney Virtual Conference at 11:00 AM ET/8:00 AM PT and the JonesTrading Healthcare Seaside Summit at 1:15 PM ET/10:15 AM PT. Live webcasts of these presentations will be available on CalciMedica's Investor Relations website and will be archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
-
Rhea-AI Summary

CalciMedica, a biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, announced its inclusion in the Russell Microcap® Index. The inclusion will be effective from July 1, 2024, following the Russell U.S. Indexes annual reconstitution, which ranks the 4,000 largest U.S. stocks by market capitalization. This marks a significant milestone for CalciMedica, highlighting its growth since going public in Q1 2023. Russell indexes are key benchmarks for investment managers and institutional investors, representing $10.5 trillion in assets as of December 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
none
Rhea-AI Summary

CalciMedica announced positive topline data from its Phase 2b CARPO trial evaluating Auxora™ in treating acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The trial met its primary objective, showing a statistically significant dose response. Key findings include up to a 43.6% reduction in median time to solid food tolerance, a 61.7% reduction in severe organ failure, and a 100% reduction in hospital stays longer than 21 days. The trial demonstrated Auxora's safety and tolerability, with plans for a Phase 3 trial and an upcoming FDA meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.4%
Tags
-
Rhea-AI Summary

CalciMedica announced it will host a conference call on June 27, 2024, at 8:30 a.m. ET to discuss topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS). The clinical-stage biopharmaceutical company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. Interested parties can join the call via a live webcast or dial-in numbers provided on CalciMedica's investor relations website. A webcast replay will be available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.4%
Tags
conference call conferences clinical trial
-
Rhea-AI Summary

CalciMedica reported a significant quarter ending March 31, 2024, marked by the completion of enrollment for the Phase 2b CARPO trial for Auxora™ in acute pancreatitis (AP), with topline data expected in 2Q 2024.

Additionally, the KOURAGE Phase 2 trial for severe acute kidney injury (AKI) will start patient enrollment in 2Q 2024, with data expected in 2025. A related abstract will be presented at Digestive Disease Week (DDW) 2024.

Financially, the company completed a $54 million private placement, with $20.4 million received upfront and $33.1 million pending from warrant exercises. With $25.7 million in cash and equivalents, operations are funded into the second half of 2025. Total operating losses were $5.8 million for Q1, offset by a $5.6 million gain from warrant liability adjustment, resulting in a $0.1 million net income.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
Rhea-AI Summary

CalciMedica Inc. announces an upcoming presentation at Digestive Disease Week 2024 where collaborators from Cedars-Sinai will present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis. The presentation will highlight the similarities between the benefits of Auxora and those seen in COVID-19 pneumonia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences
-
Rhea-AI Summary
CalciMedica Inc. announces the successful enrollment of the last patient in its Phase 2b CARPO trial of Auxora™ for acute pancreatitis. The trial reached its target enrollment of 216 patients, with topline data expected in 2Q 2024. Auxora is a small molecule inhibitor of CRAC channels developed for inflammatory and immunologic illnesses. The CEO expressed gratitude towards patients and families for their trust in the trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.61%
Tags
-
Rhea-AI Summary
CalciMedica Inc. reported financial results for 2023, highlighting progress in clinical trials for Auxora™ in acute pancreatitis and severe acute kidney injury. Recent achievements include IND clearance for AKI trial, expansion of AIPT study, and successful private placement financing. The company's cash position is strong, with plans to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary
CalciMedica Inc. presented data from preclinical studies of Auxora in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference. The results showed that Auxora improved kidney function and survival in rat models of AKI, supporting the upcoming KOURAGE trial in severe AKI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags

FAQ

What is CalciMedica, Inc. focused on?

CalciMedica is focused on discovering and developing novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases.

What is Auxora™?

Auxora™ is CalciMedica's lead product candidate, a potent and selective CRAC channel inhibitor being developed for use in patients with acute inflammatory and immunologic illnesses.

What is the CARPO trial?

The CARPO trial is a Phase 2b study aimed at establishing Auxora's efficacy in treating acute pancreatitis with systemic inflammatory response syndrome (SIRS).

What are CRAC channels?

CRAC channels are calcium release-activated calcium channels targeted by CalciMedica's proprietary technology to modulate the immune response and protect against tissue cell injury.

What are the latest updates from CalciMedica?

Recent updates include positive results from the Phase 1/2 CRSPA study, FDA clearance for the KOURAGE trial, and successful enrollment in the CARPO trial.

How is CalciMedica funded?

CalciMedica recently raised up to $55 million in gross proceeds through a securities purchase agreement, supporting ongoing and planned clinical trials.

Where is CalciMedica headquartered?

CalciMedica is headquartered in La Jolla, CA.

Are there any approved therapies for the diseases CalciMedica targets?

Currently, there are no approved therapies for many of the life-threatening inflammatory and immunologic diseases that CalciMedica targets with its CRAC channel inhibitors.

What is the KOURAGE trial?

The KOURAGE trial is a Phase 2 study evaluating Auxora in patients with acute kidney injury associated with acute hypoxemic respiratory failure. Data is expected in 2025.

Who founded CalciMedica?

CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research.

CalciMedica, Inc.

Nasdaq:CALC

CALC Rankings

CALC Stock Data

52.56M
10.75M
14.67%
59.64%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LA JOLLA